Aker BioMarine ASA (OSL:AKBM) Total Liabilities : kr4,869 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aker BioMarine ASA Total Liabilities?

Aker BioMarine ASA's Total Liabilities for the quarter that ended in Mar. 2024 was kr4,869 Mil.

Aker BioMarine ASA's quarterly Total Liabilities declined from Sep. 2023 (kr4,915.13 Mil) to Dec. 2023 (kr4,859.05 Mil) but then increased from Dec. 2023 (kr4,859.05 Mil) to Mar. 2024 (kr4,868.83 Mil).

Aker BioMarine ASA's annual Total Liabilities increased from Dec. 2021 (kr3,476.58 Mil) to Dec. 2022 (kr4,383.80 Mil) and increased from Dec. 2022 (kr4,383.80 Mil) to Dec. 2023 (kr4,859.05 Mil).

Aker BioMarine ASA Total Liabilities Historical Data

The historical data trend for Aker BioMarine ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aker BioMarine ASA Total Liabilities Chart

Aker BioMarine ASA Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4,851.99

2,849.50

3,476.58

4,383.80

4,859.05

Aker BioMarine ASA Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															4,853.28	5,046.24	4,915.13	4,859.05	4,868.83

Aker BioMarine ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aker BioMarine ASA's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1191.027	+	(3628.994	+	39.033
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,859

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	8725.409	-	3866.355
	=	4,859

Aker BioMarine ASA's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1204.473	+	(3617.665	+	46.693
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,869

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	8632.943	-	3764.112
	=	4,869

Aker BioMarine ASA Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aker BioMarine ASA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aker BioMarine ASA (OSL:AKBM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Aker BioMarine ASA (OSL:AKBM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

1PG:Germany

Address

Oksenoyveien 10, P.O. Box 496, Lysaker, NOR, NO-1327

Website

https://www.akerbiomarine.com

Aker BioMarine ASA is a supplier of krill-derived products, with a fully owned supply chain. The operations of the company span from harvesting krill in Antarctica with vessels owned by the company including distribution worldwide from Uruguay, and further processing of the krill into oil products in the United States. The segments of the company include 1) The Ingredients segment involves offshore harvesting and production, logistical operations, and onshore manufacturing and sales of krill-derived products. 2) The Brands segment focuses on human consumer goods, with Lang Pharma Nutrition (Lang) and Epion as its two main components. Lang produces and distributes private-label vitamins and supplements to retailers in the U.S. market and Epion is Aker BioMarine's consumer brand company.

Aker BioMarine ASA (OSL:AKBM) Headlines

No Headlines